

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 00504731

Reviewer's country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-16 05:42

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript reported a case pigmentation after treatment with paclitaxel. The author also reviewed the literature on this phenotype, and provided some pathological examination of the pigmentation area. The manuscript is well written and is worthy of publication.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 02680711

Reviewer's country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-23 02:40

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> [Y] Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> Grade E: Poor	language polishing	<input checked="" type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

Title: Paclitaxel-Associated Reticulate Hyperpigmentation: Report and Review Of Chemotherapy-Induced Reticulate Hyperpigmentation

General comments to author and editor This report chronicles the development of a dermal toxic reaction presumably due to paclitaxel. The reaction and report of such is, in one instance, somewhat unique, yet at the same time, potentially confounding. Specific comments to the author 1. As written, the skin reaction appears to be closely related to paclitaxel. However, in order for the skeptical reader to be convinced, it is important to include Naranjo scoring. 2. The discussion section is lengthy and could easily be contracted; the conclusion as well. 3. Lastly, it would be of interest to know if this patient has a history of allergies or allergic reactions. In summary, the paper is informative though not necessarily provocative. The incidence of this particular drug-related toxicity is relatively low. While the paper may be of interest to some, I suspect, overall, it will have little impact.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 00504024

Reviewer's country: China

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-24 05:49

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

It is interesting and worthy for publication.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 00505633

Reviewer's country: Germany

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-25 19:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

nicely written

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 01560575

Reviewer's country: Japan

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-28 18:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Major comments Cohen PR reported a case with paclitaxel-associated reticulate hyperpigmentation and reviewed ten cases of a same kind. English writing is excellent and this case report may be acceptable for publication in World Journal of Case Reports if some minor comments listed below are addressed. Minor comments 1. Provide page number in the manuscript. 2. Page 8, lines 4. ...[D]uring...her fourth cycle...she was... should be During her fourth cycle, she. 3. Page 11, lines 16. "The hyperpigmentation partially or ccompleted resolved in 83%" should be "The hyperpigmentation partially or completely resolved in 83%." 4. Provide figures of biopsy specimen histology of normal skin for comparison against reticulate hyperpigmentation.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

ESPS manuscript NO: 28069

Title: Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation

Reviewer's code: 01559576

Reviewer's country: Japan

Science editor: Fang-Fang Ji

Date sent for review: 2016-06-29 17:14

Date reviewed: 2016-07-31 17:30

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Major The patient experienced malar hyperpigmentation by the preceding capecitabine and reticulate hyperpigmentation by paclitaxel. Do the authors think that these two hyperpigmentation occurred by the same mechanisms? If no, how was the each mechanism? Discussion is too long, and redundant description should be avoided. Table 1 expresses most part of discussions. For example, paragraphs 1 to 6 of the discussion section could be omitted because they are provided in table 1. In discussion, the putative or plausible mechanisms why reticulate hyperpigmentation could occur should be described. Minor The regimens of paclitaxel should be provided. Did the patient receive premedication to prevent hypersensitivity reactions? The photos of interface dermatitis should be provided and discuss the difference from reticular hyperpigmentation. Did the reticular hyperpigmentation occur by faslodex and palbociclib? What is (6/7. X%)? For the review of the literature, the key words for electronic search and Database should be described in the Methods. In discussion, the authors described breast cancer being the most common solid tumor; however, from only 10 case records (table 1), the incidence of malignancies showing reticulate hyperpigmentation could not be



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

concluded.